Literature DB >> 10608622

Postlicensure study of varicella vaccine effectiveness in a day-care setting.

D A Clements1, S P Moreira, P M Coplan, C L Bland, E B Walter.   

Abstract

BACKGROUND: Varicella vaccine has been licensed for use in the United States since the spring of 1995. The acceptance of the vaccine and its effect on varicella incidence in children is important. AIM: To document the effectiveness of the varicella vaccine in children attending day care in 11 centers in North Carolina.
METHODS: A dynamic cohort study design was used in 11 day-care centers in North Carolina. Multiple cross-sectional evaluations were performed and children were noted to be vaccinated or not and diseased or not. Vaccine effectiveness was estimated by comparing the varicella attack rate in the vaccinated with the varicella attack rate in the unvaccinated. Person time was used as the denominator for all calculations.
RESULTS: During the study period February 1, 1996, to September 1, 1997, 134 cases of varicella occurred in the unvaccinated and 11 cases occurred in the vaccinated children. The attack rates in the vaccinated and unvaccinated were 2.49 and 14.66, respectively, for an overall vaccine effectiveness of 83% for mild/moderate disease.
CONCLUSIONS: In the day-care setting varicella vaccine demonstrated benefit in preventing and modifying wild-type varicella disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608622     DOI: 10.1097/00006454-199912000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Attitudes and practices regarding varicella vaccination among physicians in Minnesota: implications for public health and provider education.

Authors:  K R Ehresmann; W A Mills; P R Loewenson; K A Moore
Journal:  Am J Public Health       Date:  2000-12       Impact factor: 9.308

Review 2.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

Review 3.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012.

Authors:  Silvio Tafuri; Francesca Fortunato; Maria Giovanna Cappelli; Vanessa Cozza; Angela Bechini; Paolo Bonanni; Domenico Martinelli; Rosa Prato
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

5.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

Review 6.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Varicella and varicella vaccination in South Korea.

Authors:  Sung Hee Oh; Eun Hwa Choi; Seon Hee Shin; Yun-Kyung Kim; Jin Keun Chang; Kyong Min Choi; Jae Kyun Hur; Kyung-Hyo Kim; Jae Youn Kim; Eun Hee Chung; Soo Young Lee; Su Eun Park; Sungho Cha; Kwang-Nam Kim; Sang Hyuk Ma; Byung Wook Eun; Nam Hee Kim; Dae Sun Jo; Bo Youl Choi; Shin Ah Kim
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

8.  Length of stay and hospital readmission for persons with disabilities.

Authors:  K J Ottenbacher; P M Smith; S B Illig; R C Fiedler; C V Granger
Journal:  Am J Public Health       Date:  2000-12       Impact factor: 9.308

9.  Three-year follow-up of protection rates in children given varicella vaccine.

Authors:  David W Scheifele; Scott A Halperin; Francisco Diaz-Mitoma
Journal:  Can J Infect Dis       Date:  2002-11

10.  A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Authors:  Gary S Marshall; Shelly D Senders; Julie Shepard; Jerry D Twiggs; Julie Gardner; Darcy Hille; Jonathan Hartzel; Rowan Valenzuela; Jon E Stek; Frans A Helmond
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.